PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target

• DOI: 10.1371/journal.pone.0224085
• Publication Date: 2019-10-23T15:08:45Z
• Authors: Holger Hans Herma...; Marlies Ebert; Ronja Kuhn; Lukas Donix; Axel Haferkamp; Robert Ian Seed; Eva Jüngel
• Keywords: STAT1

Urothelial cancer (UC) is one of the most common cancers in Europe and also costliest to treat. When first line therapies show initial success, around 50% relapse proceed metastasis. In this study we assessed Protein inhibitor activated signal transducers activators transcription (PIAS)1 as a potential therapeutic target urothelial cancer. PIAS1 key regulator STAT1 signalling may be implicated carcinogenesis. contrast other types protein expression not significantly different malignant areas UC specimens compared non-malignant tissue. addition, found that down-regulation overexpression had no effect on viability or colony forming ability tested cell lines. Whilst studies suggest an important biological role cancer, shows has influence reducing cytotoxic effects Cisplatin recovery after DNA damage induced by irradiation. Taken together, these vitro data demonstrate promising previously shown entities such prostate (PCa).